Parkinsons Disease Psychosis Pipeline Insight

DelveInsight’s, "Parkinson’s disease psychosis - Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parkinson’s disease psychosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Parkinson’s disease psychosis Understanding

Parkinson’s disease psychosis: Overview

Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition. Psychosis in PD patients is mostly arising in patients with a clear sensorium in a chronic setting after a long disease duration and is triggered or enhanced by pharmacological factors. Nonetheless, other recent risk factors have been studied, giving rise to a potential multifactorial underlying aetiology and thus physiopathology. The differentiation between early and late onset psychosis in general, and also specifically in PD, is not currently validated, having some studies randomly set cut-off values at 2–4 years of PD onset to determine early versus late onset psychosis.

"Parkinson’s disease psychosis - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease psychosis pipeline landscape is provided which includes the disease overview and Parkinson’s disease psychosis treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease psychosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease psychosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Parkinson’s disease psychosis. The therapies under development are focused on novel approaches to treat/improve Parkinson’s disease psychosis.

Parkinson’s disease psychosis Emerging Drugs

Iloperidone: Vanda Pharmaceuticals

Iloperidone belongs to a class of medications for schizophrenia known as atypical antipsychotics. Acceptance of the NDA application confirms that the application is sufficiently complete for FDA review for the treatment of schizophrenia.

Ulotaront: Sumitomo Pharma

Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion and PsychoGenics Inc, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.

Further product details are provided in the report……..

Parkinson’s disease psychosis: Therapeutic Assessment

This segment of the report provides insights about the Parkinson’s disease psychosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Parkinson’s disease psychosis

There are approx. 5+ key companies which are developing the therapies Parkinson’s disease psychosis. The companies which have their Parkinson’s disease psychosis drug candidates in the most advanced stage, i.e phase II include Vanda Pharmaceuticals

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Parkinson’s disease psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Parkinson’s disease psychosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Parkinson’s disease psychosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease psychosis drugs.

Parkinson’s disease psychosis Report Insights

• Parkinson’s disease psychosis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Parkinson’s disease psychosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Parkinson’s disease psychosis drugs?
• How many Parkinson’s disease psychosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s disease psychosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s disease psychosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Parkinson’s disease psychosis and their status?
• What are the key designations that have been granted to the emerging drugs?